For example, treatment of NF1-deficient lung cancers with map-ERK kinase (MEK) inhibitors restores sensitivity to erlotinib [25]; and combining type II Rafi with an allosteric MEKI reliably prevents and overcomes acquired drug resistance in cancers with NF1 mutations. This evidence concerns the gene MAP2K7 and cancer.